Results 41 to 50 of about 1,825,071 (265)

Oral epithelial IL-22/STAT3 signaling licenses IL-17–mediated immunity to oral mucosal candidiasis

open access: yesScience immunology, 2020
IL-22 signaling limits oral candidiasis via proliferation of basal epithelial cells and replenishment of an IL-17–responsive layer. Type 17 tag team Effective immune defense against invasive oral infections by the fungus Candida albicans relies heavily ...
Felix E. Y. Aggor   +16 more
semanticscholar   +1 more source

Immunology of oral candidiasis

open access: yesJournal of Pharmacy And Bioallied Sciences, 2014
A successful pathogen is one that is able to effectively survive and evade detection by the host immune defense. Oral candidiasis has adopted strategies, which evade host defense and eventually cause disease in at-risk patients. Host defense against infections with Candida spp.
P Udayakumar   +5 more
openaire   +4 more sources

Oral candidiasis: An overview

open access: yesJournal of Oral and Maxillofacial Pathology, 2014
Candida is the shortened name used to describe a class of fungi that includes more than 150 species of yeast. In healthy individuals, Candida exists harmlessly in mucus membranes such as your ears, eyes, gastrointestinal tract, mouth, nose, reproductive organs, sinuses, skin, stool and vagina, etc.
Ashutosh Agrawal   +3 more
openaire   +4 more sources

Vaginal yeasts in the era of "over the counter" antifungals [PDF]

open access: yes, 2000
OBJECTIVE: To establish whether there has been any rise in the prevalence of non-albicans Candida species isolated from vaginal swabs since the introduction of “over the counter” antifungal treatments.
Ashbee, H.R.   +4 more
core   +2 more sources

Oral candidiasis in non‐severe COVID‐19 patients: call for antibiotic stewardship

open access: yesOral Surgery, 2020
Bacterial/fungal coinfection is a suggested etiological theory for the COVID-19 related oral manifestations that may trigger overprescribing of broad-spectrum antibiotics for COVID-19 patients, especially for the ones who experience a longer course of ...
Abanoub Riad   +3 more
semanticscholar   +1 more source

Miconazole in Oral Candidiasis [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1977
Twenty-four patients were treated with oral miconazole (250 mg) for a total of 35 episodes of oral candidiasis. Sixteen had various forms of leukaemia and all were massively predisposed to fungal infection because of granulocytopenia and treatment with prednisolone and antibiotics.
openaire   +3 more sources

Steroids in pediatric eosinophilic esophagitis [PDF]

open access: yes, 2014
Swallowed fluticasone and oral viscous budesonide are effective first-line therapies for eosinophilic esophagitis in children. Side effects are minimal without evidence of Cushing syndrome, as seen in treatment with systemic corticosteroids.
Contreras, Emily M., Gupta, Sandeep K.
core   +1 more source

Factors Associated with Oral Candidiasis in People Living with HIV/AIDS: A Case Control Study

open access: yesHIV/AIDS, 2020
Background Oral candidiasis (OC) is the most frequent opportunistic infection of the oral cavity caused by Candida species overgrowth. A wide variety of risk factor that contributes to yeast infection especially candidiasis.
K. Suryana   +3 more
semanticscholar   +1 more source

Clinical periodontal diagnosis

open access: yesPeriodontology 2000, EarlyView., 2023
Abstract Periodontal diseases include pathological conditions elicited by the presence of bacterial biofilms leading to a host response. In the diagnostic process, clinical signs such as bleeding on probing, development of periodontal pockets and gingival recessions, furcation involvement and presence of radiographic bone loss should be assessed prior ...
Giovanni E. Salvi   +5 more
wiley   +1 more source

Oral candidiasis in HIV+ patients under treatment with protease inhibitors [PDF]

open access: yes, 2008
The purpose of this work was to evaluate the influence of Protease Inhibitors (PI) on the occurrence of oral candidiasis in 111 HIV+ patients under PI therapy (Group A).
LOTUFO, Mônica Andrade   +3 more
core   +2 more sources

Home - About - Disclaimer - Privacy